1. Cardiovasc Res. 2022 Mar 16;118(4):1088-1102. doi: 10.1093/cvr/cvab136.

Cis-epistasis at the LPA locus and risk of cardiovascular diseases.

Zeng L(1), Moser S(2)(3), Mirza-Schreiber N(2)(4), Lamina C(5), Coassin S(5), 
Nelson CP(6)(7), Annilo T(8), Franzén O(9)(10), Kleber ME(11), Mack S(5), 
Andlauer TFM(2)(12), Jiang B(2), Stiller B(1), Li L(1), Willenborg C(13), Munz 
M(13)(14)(15), Kessler T(1)(16), Kastrati A(1)(16), Laugwitz KL(17), Erdmann 
J(13)(14), Moebus S(18)(19), Nöthen MM(20), Peters A(21)(22), Strauch 
K(21)(22)(23), Müller-Nurasyid M(21)(22)(23)(24), Gieger C(21)(25), Meitinger 
T(26), Steinhagen-Thiessen E(27), März W(11)(28), Metspalu A(8)(29), Björkegren 
JLM(9)(10), Samani NJ(6)(7), Kronenberg F(5), Müller-Myhsok B(2)(30)(31), 
Schunkert H(1)(14).

Author information:
(1)Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen, 
Technische Universität München, 80636 Munich, Germany.
(2)Department of Translational Research in Psychiatry, Max Planck Institute of 
Psychiatry, 80804 Munich, Germany.
(3)International Max Planck Research School for Translational Psychiatry 
(IMPRS-TP), Munich 80804, Germany.
(4)Institute of Neurogenomics, Helmholtz Zentrum München, 85764 Neuherberg, 
Germany.
(5)Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, 
Medical University of Innsbruck, Innsbruck 6020, Austria.
(6)Department of Cardiovascular Sciences, University of Leicester, BHF 
Cardiovascular Research Centre, Glenfield Hospital, Groby Rd, Leicester LE3 9QP, 
UK.
(7)NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester LE3 
9QP, UK.
(8)Estonian Genome Center, Institute of Genomics, University of Tartu, 51010 
Tartu, Estonia.
(9)Department of Genetics and Genomic Sciences and Institute for Genomics and 
Multiscale Biology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy 
Place, New York, NY 10029, USA.
(10)Integrated Cardio Metabolic Centre, Karolinska Institutet, Huddinge, 14186 
Stockholm, Sweden.
(11)Medizinische Klinik V (Nephrologie, Hypertensiologie, Rheumatologie, 
Endokrinologie, Diabetologie), Medizinische Fakultät Mannheim der Universität 
Heidelberg, 69120 Heidelberg, Germany.
(12)Department of Neurology, Klinikum rechts der Isar, School of Medicine, 
Technical University of Munich, 81675 Munich, Germany.
(13)Institute for Cardiogenetics and University Heart Center Luebeck, University 
of Lübeck, 23562 Lübeck, Germany.
(14)Deutsches Zentrum für Herz- und Kreislauf-Forschung (DZHK), Partner Site 
Hamburg/Lübeck/Kiel, 23562 Lübeck, Germany.
(15)Charité - University Medicine Berlin, Corporate Member of Freie Universität 
Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 
Institute for Dental and Craniofacial Sciences, Department of Periodontology and 
Synoptic Dentistry, 14197 Berlin, Germany.
(16)Deutsches Zentrum für Herz- und Kreislauf-Forschung (DZHK), Partner Site 
Munich Heart Alliance, 80636 Munich, Germany.
(17)Medizinische Klinik, Klinikum rechts der Isar, Technische Universität 
München, 81675 Munich, Germany.
(18)Institute for Medical Informatics, Biometry and Epidemiology, University 
Hospital Essen, 45147 Essen, Germany.
(19)Centre for Urbane Epidemiology, University Hospital Essen, 45147 Essen, 
Germany.
(20)Institute of Human Genetics, University of Bonn School of Medicine & 
University Hospital Bonn, 53012 Bonn, Germany.
(21)Institute of Genetic Epidemiology, Helmholtz Zentrum München, German 
Research Center for Environmental Health, 85764 Neuherberg, Germany.
(22)IBE, Faculty of Medicine, LMU Munich, 81377 Munich, Germany.
(23)Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), 
University Medical Center, Johannes Gutenberg University, 55101 Mainz, Germany.
(24)Department of Internal Medicine I (Cardiology), Hospital of the 
Ludwig-Maximilians-University (LMU) Munich, 81377 Munich, Germany.
(25)Institute of Epidemiology II, Helmholtz Zentrum München, 85764 Neuherberg, 
Germany.
(26)Institute of Human Genetics, Helmholtz Zentrum München, 85764 Neuherberg, 
Germany.
(27)Center for Internal Medicine with Gastroenterology and Nephrology, Lipid 
Clinic, Charité, 13353 Berlin, Germany.
(28)Synlab Akademie, Synlab Holding Deutschland GmbH, Mannheim und Augsburg, 
86156 Augsburg, Germany.
(29)Institute of Molecular and Cell Biology, University of Tartu, 51010 Tartu, 
Estonia.
(30)Munich Cluster of Systems Biology, SyNergy, 81377 Munich, Germany.
(31)Department of Health Data Science, University of Liverpool, Liverpool L69 
3BX, UK.

AIMS: Coronary artery disease (CAD) has a strong genetic predisposition. 
However, despite substantial discoveries made by genome-wide association studies 
(GWAS), a large proportion of heritability awaits identification. Non-additive 
genetic effects might be responsible for part of the unaccounted genetic 
variance. Here, we attempted a proof-of-concept study to identify non-additive 
genetic effects, namely epistatic interactions, associated with CAD.
METHODS AND RESULTS: We tested for epistatic interactions in 10 CAD case-control 
studies and UK Biobank with focus on 8068 SNPs at 56 loci with known 
associations with CAD risk. We identified a SNP pair located in cis at the LPA 
locus, rs1800769 and rs9458001, to be jointly associated with risk for CAD [odds 
ratio (OR) = 1.37, P = 1.07 × 10-11], peripheral arterial disease (OR = 1.22, 
P = 2.32 × 10-4), aortic stenosis (OR = 1.47, P = 6.95 × 10-7), hepatic 
lipoprotein(a) (Lp(a)) transcript levels (beta = 0.39, P = 1.41 × 10-8), and 
Lp(a) serum levels (beta = 0.58, P = 8.7 × 10-32), while individual SNPs 
displayed no association. Further exploration of the LPA locus revealed a strong 
dependency of these associations on a rare variant, rs140570886, that was 
previously associated with Lp(a) levels. We confirmed increased CAD risk for 
heterozygous (relative OR = 1.46, P = 9.97 × 10-32) and individuals homozygous 
for the minor allele (relative OR = 1.77, P = 0.09) of rs140570886. Using 
forward model selection, we also show that epistatic interactions between 
rs140570886, rs9458001, and rs1800769 modulate the effects of the rs140570886 
risk allele.
CONCLUSIONS: These results demonstrate the feasibility of a large-scale 
knowledge-based epistasis scan and provide rare evidence of an epistatic 
interaction in a complex human disease. We were directed to a variant 
(rs140570886) influencing risk through additive genetic as well as epistatic 
effects. In summary, this study provides deeper insights into the genetic 
architecture of a locus important for cardiovascular diseases.

© The Author(s) 2021. Published by Oxford University Press on behalf of the 
European Society of Cardiology.

DOI: 10.1093/cvr/cvab136
PMCID: PMC8930071
PMID: 33878186 [Indexed for MEDLINE]